Imugene Limited (ASX:IMU) Managing Director & CEO, Leslie Chong presents on the company's trial progress with its lead HER-Vaxx cancer vaccine, advantages of B-cell vaccines and strengthened scientific board at FNN's Investor Event.
- Develops vaccines to boost the immune system to attack cancer cells
- Harnessing B-cells for cancer immunotherapy
- Broadened clinical programs globally, including U.S. and European centres
- HER-Vaxx milestones of Phase 1b recruitment completed
- Phase 2 activity commenced
- B-Vaxx Phase 2 ongoing
- KEY-Vaxx pre-clinical work started
- Synergistic technology licensed from Ohio State University and The Mayo Clinic
For more watch Managing Director and CEO, Leslie Chong present.